Clinical safety and efficacy study of TruUCAR (TM) GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)
机构:[1]Gracell Biotechnol Co Ltd, Shanghai, Peoples R China[2]920th Hosp OfJoint Logist Support Force Peoples C, Kunming, Yunnan, Peoples R China[3]Army Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China[4]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China昆明医科大学附属第一医院
第一作者机构:[1]Gracell Biotechnol Co Ltd, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Wang Xinxin,Li Shiqi,Gao Lei,et al.Clinical safety and efficacy study of TruUCAR (TM) GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)[J].CANCER RESEARCH.2020,80(16):doi:10.1158/1538-7445.AM2020-CT052.
APA:
Wang, Xinxin,Li, Shiqi,Gao, Lei,Yuan, Zhongtao,Wu, Kun...&Zhang, Xi.(2020).Clinical safety and efficacy study of TruUCAR (TM) GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).CANCER RESEARCH,80,(16)
MLA:
Wang, Xinxin,et al."Clinical safety and efficacy study of TruUCAR (TM) GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)".CANCER RESEARCH 80..16(2020)